These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 7612698)

  • 41. Protection against a lethal challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen.
    Bright RK; Beames B; Shearer MH; Kennedy RC
    Cancer Res; 1996 Mar; 56(5):1126-30. PubMed ID: 8640771
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of a subdominant H-2Kd-restricted SV40 tumor antigen cytotoxic T lymphocyte epitope in tumor rejection.
    Newmaster RS; Mylin LM; Fu TM; Tevethia SS
    Virology; 1998 May; 244(2):427-41. PubMed ID: 9601511
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Humoral and cellular immunity to an encoded protein induced by direct DNA injection.
    Katsumi A; Emi N; Abe A; Hasegawa Y; Ito M; Saito H
    Hum Gene Ther; 1994 Nov; 5(11):1335-9. PubMed ID: 7893804
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulatory issues in the use of DNA vaccines.
    Minor PD
    Ann N Y Acad Sci; 1995 Nov; 772():170-7. PubMed ID: 8546390
    [No Abstract]   [Full Text] [Related]  

  • 45. Cellular and humoral immune responses against cancer: implications for cancer vaccines.
    Knuth A; Wölfel T; Meyer zum Büschenfelde KH
    Curr Opin Immunol; 1991 Oct; 3(5):659-64. PubMed ID: 1755985
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of recombinant interleukin 2 (R-IL2) on in vivo growth of murine myeloma X5563.
    Maekawa R; Matsumoto M; Kitagawa T; Harada M; Sato K
    Cancer Immunol Immunother; 1986; 23(1):25-30. PubMed ID: 3490306
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy.
    Dhodapkar MV; Sexton R; Das R; Dhodapkar KM; Zhang L; Sundaram R; Soni S; Crowley JJ; Orlowski RZ; Barlogie B
    Blood; 2015 Nov; 126(22):2475-8. PubMed ID: 26468228
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ELI's coming: expression library immunization and vaccine antigen discovery.
    Ulmer JB; Liu MA
    Trends Microbiol; 1996 May; 4(5):169-70; discussion 170-1. PubMed ID: 8727594
    [No Abstract]   [Full Text] [Related]  

  • 49. Adjuvant effects of L. acidophilus LW1 on immune responses to the foot-and-mouth disease virus DNA vaccine in mice.
    Su J; Li J; Zheng H; You Y; Luo X; Li Y; Li X; Ma X; Li J; Dou Y; Cai X
    PLoS One; 2014; 9(8):e104446. PubMed ID: 25119375
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.
    Rosenberg SA; Yang JC; Sherry RM; Hwu P; Topalian SL; Schwartzentruber DJ; Restifo NP; Haworth LR; Seipp CA; Freezer LJ; Morton KE; Mavroukakis SA; White DE
    Hum Gene Ther; 2003 May; 14(8):709-14. PubMed ID: 12804135
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cellular but not humoral immune responses generated by vaccination with dendritic cells protect mice against leukaemia.
    Colombo BM; Lacave R; Pioche-Durieu C; Masurier C; Lemoine FM; Guigon M; Klatzmann D
    Immunology; 2000 Jan; 99(1):8-15. PubMed ID: 10651935
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunophenotypical and functional heterogeneity of dendritic cells generated from murine bone marrow cultured with different cytokine combinations: implications for anti-tumoral cell therapy.
    Masurier C; Pioche-Durieu C; Colombo BM; Lacave R; Lemoine FM; Klatzmann D; Guigon M
    Immunology; 1999 Apr; 96(4):569-77. PubMed ID: 10233743
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prospects for the therapeutic use of anticancer vaccines.
    Chamberlain RS
    Drugs; 1999 Mar; 57(3):309-25. PubMed ID: 10193685
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions.
    Vile RG; Chong H
    Cancer Metastasis Rev; 1996 Sep; 15(3):351-64. PubMed ID: 9034596
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The next wave of recombinant and synthetic anticancer vaccines.
    Irvine KR; Restifo NP
    Semin Cancer Biol; 1995 Dec; 6(6):337-47. PubMed ID: 8938272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New therapeutic approaches based on gene transfer techniques.
    Chong H; Vile RG
    Springer Semin Immunopathol; 1996; 18(2):149-70. PubMed ID: 8908697
    [No Abstract]   [Full Text] [Related]  

  • 57. Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1.
    Büeler H; Mulligan RC
    Mol Med; 1996 Sep; 2(5):545-55. PubMed ID: 8898371
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunotherapeutic strategies targeting rheumatoid synovial T-cell receptors by DNA inoculation.
    Williams WV; Fang Q; Von Feldt JM; Boyer JD; Luchi M; Wang B; Weiner DB
    Immunol Res; 1994; 13(2-3):145-53. PubMed ID: 7775805
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunization by direct DNA inoculation induces rejection of tumor cell challenge.
    Wang B; Merva M; Dang K; Ugen KE; Williams WV; Weiner DB
    Hum Gene Ther; 1995 Apr; 6(4):407-18. PubMed ID: 7612698
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
    Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
    Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.